Difference between revisions of "Pegaspargase (Oncaspar)"
m |
|||
Line 1: | Line 1: | ||
− | |||
− | |||
==General information== | ==General information== | ||
− | Class/mechanism: Depletes plasma asparagine, selectively killing leukemic cells which are unable to synthesize asparagine due to a lack of asparagine synthetase. The Oncaspar formulation involves L-asparaginase (L-asparagine amidohydrolase) being covalently conjugated to monomethoxypolyethylene glycol (mPEG), increasing its half-life and reducing the risk of hypersensitivity reactions in patients who have history of hypersensitivity to [[Asparaginase (Elspar)]].<ref name="insert">[http:// | + | Class/mechanism: Depletes plasma asparagine, selectively killing leukemic cells which are unable to synthesize asparagine due to a lack of asparagine synthetase. The Oncaspar formulation involves L-asparaginase (L-asparagine amidohydrolase) being covalently conjugated to monomethoxypolyethylene glycol (mPEG), increasing its half-life and reducing the risk of hypersensitivity reactions in patients who have history of hypersensitivity to [[Asparaginase (Elspar)]].<ref name="insert">[http://www.shirecontent.com/PI/PDFs/ONCASPAR_USA_ENG.pdf Pegaspargase (Oncaspar) package insert]</ref><ref>[[Media:Pegaspargase.pdf | Pegaspargase (Oncaspar) package insert (locally hosted backup)]]</ref> |
<br>Route: IV, IM | <br>Route: IV, IM | ||
− | <br>Extravasation: | + | <br>Extravasation: [[neutral]] |
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
Line 19: | Line 17: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
* 2/1/1994: Initial FDA approval | * 2/1/1994: Initial FDA approval | ||
+ | |||
+ | ==Also known as== | ||
+ | Crisantaspase, PEG-L-asparaginase, Peg-asparginase, Pegasparaginase. | ||
==References== | ==References== | ||
Line 27: | Line 28: | ||
[[Category:Intramuscular chemotherapy]] | [[Category:Intramuscular chemotherapy]] | ||
[[Category:Intravenous chemotherapy]] | [[Category:Intravenous chemotherapy]] | ||
+ | [[Category:Neutral chemotherapy]] | ||
[[Category:Enzymes]] | [[Category:Enzymes]] |
Revision as of 20:28, 23 April 2017
General information
Class/mechanism: Depletes plasma asparagine, selectively killing leukemic cells which are unable to synthesize asparagine due to a lack of asparagine synthetase. The Oncaspar formulation involves L-asparaginase (L-asparagine amidohydrolase) being covalently conjugated to monomethoxypolyethylene glycol (mPEG), increasing its half-life and reducing the risk of hypersensitivity reactions in patients who have history of hypersensitivity to Asparaginase (Elspar).[1][2]
Route: IV, IM
Extravasation: neutral
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
No regimen currently listed on HemOnc.org directly references this drug. However, it is often substituted for L-asparaginase in many chemotherapy regimens, due to ease of administration.
Patient drug information
- Pegaspargase (Oncaspar) patient drug information (Chemocare)[3]
- Pegaspargase (Oncaspar) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 2/1/1994: Initial FDA approval
Also known as
Crisantaspase, PEG-L-asparaginase, Peg-asparginase, Pegasparaginase.